Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung Min Lee, Elise C. Kohn, Stanley Lipkowitz et al.|Journal of Clinical Oncology|2017Cited by 241
Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women’s cancersCody J. Peer, William D. Figg, Jung Min Lee et al.|Cancer Chemotherapy and Pharmacology|2017Cited by 10